



Supplementary Materials

Article

Combinatorial drug treatments reveal promising anticytomegaloviral profiles for clinically relevant pharmaceutical kinase inhibitors (PKIs)

Markus Wild¹, Jintawee Kicuntod¹, Lisa Seyler², Christina Wangen¹, Luca D. Bertzbach³, Andelé M. Conradie³, Benedikt B. Kaufer³, Sabrina Wagner¹, Detlef Michel⁴, Jan Eickhoff⁵, Svetlana B. Tsogoeva⁶, Tobias Bäuerle², Friedrich Hahn¹, Manfred Marschall^{1,*}

¹ Institute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany; markus.wild@uk-erlangen.de, jintawee.kicuntod@extern.uk-erlangen.de, christina.wangen@uk-erlangen.de, sabrina.wagner@uk-erlangen.de, friedrich.hahn@uk-erlangen.de, manfred.marschall@fau.de

² Institute of Radiology, University Medical Center Erlangen, FAU, Palmsanlage 5, 91054 Erlangen, Germany; lisa.seyler@uk-erlangen.de, tobias.baerle@uk-erlangen.de

³ Institute of Virology, Freie Universität Berlin, Robert-von-Ostertag-Straße 7-13, 14163 Berlin, Germany; luca.bertzbach@fu-berlin.de; andele.conradie@fu-berlin.de; benedikt.kaufer@fu-berlin.de

⁴ Institute for Virology, Ulm University Medical Center, Albert-Einstein-Allee 11, Ulm, Germany; detlef.michel@uniklinik-ulm.de

⁵ Lead Discovery Center GmbH, Otto-Hahn-Str. 15, 44227 Dortmund, Germany; eickhoff@lead-discovery.de

⁶ Institute of Organic Chemistry I, FAU, Nikolaus-Fiebiger-Straße 10, 91058 Erlangen Germany; svetlana.tsogoeva@fau.de

* Correspondence: manfred.marschall@fau.de; Tel.: ++49 9131 8526089

Received: date; Accepted: date; Published: date




Figure S1. Scheme of the HCMV replication cycle illustrating the distinct modes of action of approved direct-acting antivirals (DAAs; i.e. ganciclovir, foscarnet, cidofovir, acyclovir, letermovir), developmental DAA (maribavir) and host-directed antivirals (HDAs; i.e. artesunate-like drugs, abemaciclib, LDC4297).